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Abstract  35 
Osteoarthritis (OA) is a common degenerative joint disease, characterised by cartilage loss and 36 
subchondral bone remodelling in response to abnormal mechanical load. Heparan sulfate (HS) 37 
proteoglycans bind to many proteins that regulate cartilage homeostasis, including growth factors, 38 
morphogens, proteases and their inhibitors, and modulate their localization, retention and biological 39 
activity. Changes in HS expression and structure may thus have important consequences for joint health. 40 
We analysed normal and osteoarthritic human knee cartilage, and found HS biosynthesis was markedly 41 
disrupted in OA, with 45% of the 38 genes analysed differentially regulated in diseased cartilage. 42 
Expression of several HS core proteins, biosynthesis and modification enzymes was increased in OA 43 
cartilage, while expression of the HS proteoglycans syndecan 4 and betaglycan was reduced. The 44 
structure of HS was also altered, with increased levels of 6-O-sulfation in osteoarthritic samples. This 45 
correlated with increased expression of HS6ST1, a 6-O-sulfotransferase, and GLCE, an epimerase that 46 
promotes 6-O-sulfation. siRNA silencing of HS6ST1 expression in primary OA chondrocytes inhibited 47 
ERK phosphorylation in response to FGF2, showing that changes in 6-O-sulfation impact a key 48 
cartilage signalling pathway. Given the broad range of homeostatic and repair pathways that HS 49 
regulates, these changes in proteoglycan expression and HS structure are likely to have significant 50 
effects on joint health and progression of osteoarthritis.  51 
 52 
Introduction 53 
 54 
Osteoarthritis (OA) is a common degenerative joint disease in which articular cartilage loss and 55 
subchondral bone remodelling cause pain and impair movement of affected joints. There are currently 56 
no disease-modifying therapies available, and patients are largely treated with analgesia or joint 57 
replacement surgery. There is thus a substantial need to develop effective therapeutics that can slow or 58 
halt the progression of joint damage. 59 
The primary risk factors for development of OA are ageing and injury, which alter the mechanical 60 
environment of the joint and stimulate chondrocytes to produce catabolic proteinases that degrade the 61 
cartilage extracellular matrix. The pericellular matrix immediately adjacent to chondrocytes is thought 62 
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to play a central role in transducing mechanical stimuli to biochemical signals within the cells.1 For 63 
example, loading of cartilage causes release of fibroblast growth factor 2 (FGF2) from the pericellular 64 
matrix, and activates downstream extracellular signal-regulated kinase (ERK) signalling pathways in 65 
chondrocytes.2, 3 FGF2 is localized in the pericellular matrix through its interaction with the heparan 66 
sulfate (HS) chains of perlecan,2 the major HS proteoglycan in cartilage. Pericellular matrix and cell 67 
surface HS also binds to a large number of other bioactive proteins, including growth factors [e. g. 68 
connective tissue growth factor (CTGF) and transforming growth factor β (TGFβ)], morphogens [e. g. 69 
bone morphogenetic protein (BMP)-4 and  BMP-7], proteinases [e. g. matrix metalloproteinase 13 70 
(MMP-13), adamalysin with thrombospondin motifs 4 (ADAMTS-4), and ADAMTS-5] and proteinase 71 
inhibitors (e. g. tissue inhibitor of metalloproteinases, TIMP-3), and regulates their retention, 72 
localization and biological activity.4, 5 HS is thus a critical regulator of chondrocyte homeostasis and 73 
cartilage health. Previous studies have shown increased expression of some of the HS core proteins in 74 
OA, including perlecan,6-9 syndecan 19-11  and syndecan 4,11-13  but nothing is yet known about how the 75 
structure of HS itself or its interactions with ligands changes in OA.  76 
HS interacts with proteins through electrostatic interactions between its negatively charged sulfate 77 
groups and positively charged lysine and arginine residues on the protein ligand. The number and 78 
arrangement of sulfate groups along the HS glycosaminoglycan chain determines the affinity of HS for 79 
its protein ligands and its ability to modulate their biological activity.14-16 This sulfation pattern is 80 
generated by the template-independent action of a series of sulfotransferases during HS synthesis in the 81 
Golgi apparatus.17 The EXT family of glycosyltransferases initiate HS synthesis by adding sequential 82 
glucuronic acid (GlcA) and N-acetyl glucosamine (GlcNAc) residues to a linker tetrasaccharide 83 
attached to the core protein. GlcA can subsequently be epimerized to iduronic acid (IdoA) by glucuronyl 84 
C5-epimerase (GLCE).  The growing HS chain can then be N-sulfated on GlcNAc residues [by the N-85 
deacetylase/N-sulfotransferases (NDSTs)], and/or O-sulfated on GlcNAc [by the 6-O-sulfotransferases 86 
(HS6STs) and 3-O-sulfotransferases (HS3ST)] and GlcA/IdoA [by the 2-O-sulfotransferase 87 
(HS2ST1)].17 HS can also be edited in the extracellular environment by SULF1 and SULF2 that remove 88 
6-O-sulfate groups, or degraded by the heparanases HSPE1 and HSPE2. These reactions do not always 89 
occur to completion, generating a highly variable sulfation pattern that gives HS a structural complexity 90 
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several orders of magnitude larger than the proteome. Temporal and spatial changes in HS sulfation 91 
occur during development18-21 and in diseases such as Alzheimer’s disease22, 23, cancer,24 diabetes,25 and 92 
fibrosis,26 and are thought to enable HS to coordinately regulate the retention and activity of multiple 93 
bioactive ligands, and thus to powerfully regulate tissue homeostasis. 94 
Here, we isolated RNA from knee cartilage of normal and osteoarthritic donors, and profiled 95 
expression of the 13 core proteins and 25 biosynthesis and modifying enzymes that govern HS structure 96 
and sulfation. Notably, we also undertook the first examination of disaccharide composition by isolating 97 
HS from normal and OA cartilage. This showed that HS enzyme expression and glycan structure are 98 
markedly dysregulated in OA cartilage, and identifies increased 6-O-sulfation of HS as the primary 99 
structural change associated with impaired cartilage homeostasis.   100 
 101 
Materials and Methods 102 
 103 
Human cartilage samples 104 
 105 
Human articular cartilage was obtained in full compliance with national and institutional ethical 106 
requirements, the United Kingdom Human Tissue Act, and the Declaration of Helsinki.  107 
Normal human knee cartilage specimens used for RNA and glycosaminoglycan analyses were 108 
obtained from Articular Engineering LLC (Illinois, USA) from donors (6 females of 44-68 years old, 6 109 
males of 32-75 years old) with clinically healthy, normal cartilage and no history of OA, following 110 
informed donor consent and approval by local ethics committees and the University of Oxford Research 111 
Ethics Committee (R45926/RE001). Cartilage was aseptically harvested within 48 hours of death, flash 112 
frozen in liquid nitrogen, stored at -80oC, and shipped in dry ice. 113 
Normal human knee cartilage specimens used for immunohistochemistry were obtained from 114 
Stanmore Biobank (Royal National Orthopaedic Hospital, Stanmore) from donors undergoing 115 
amputation for low limb malignancies with no involvement of the cartilage, following informed donor 116 
consent and approval by the Royal Veterinary College Ethics and Welfare Committee (Institutional 117 
approval Unique Reference Number 2012 0048H). Cartilage was aseptically harvested from all surfaces 118 
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of the joint within 4 hours of surgery and processed for downstream analyses. 119 
Human OA cartilage samples used for immunohistochemistry, RNA and glycosaminoglycan 120 
analyses were obtained from the Oxford Musculoskeletal Biobank from donors (6 females of 58-83 121 
years old, 6 males of 52-84 years old) undergoing total knee replacement surgery for advanced OA, 122 
following informed consent and approval by the Oxford Research Ethics Committee C (09/H0606/11). 123 
Cartilage was aseptically harvested from all surfaces of the joint within 4 hours of surgery and processed 124 
for downstream analyses. 125 
 126 
RNA isolation 127 
 128 
Cartilage (300 mg) from 12 normal and 12 OA donors was ground under liquid nitrogen with a pestle 129 
and mortar. The ground cartilage powder was added to 1.5 ml of RLT lysis buffer supplemented with 130 
10 µl/ml b-mercaptoethanol (QIAGEN, UK), digested with proteinase K (6-10 mAU/100 mg of 131 
cartilage, 10 min at 55°C, QIAGEN, UK) and transferred to an RNeasy micro column (QIAGEN, UK). 132 
RNA was extracted according to the manufacturers’ protocol with an intermediate DNA digestion step. 133 
The eluted RNA was quantified on a Nanodrop spectrophotometer and examined on a Bioanalyser 134 
(Agilent, UK). RNA from healthy and OA cartilage had comparable RINs (6-7.7) and RNA yields.  135 
 136 
Reverse transcription and quantitative PCR 137 
 138 
Total RNA (250 ng) was reverse transcribed to cDNA using a reverse transcription kit (ThermoFisher) 139 
and cDNA amplified on a Taqman low density array (Table 1). Fold changes against the control samples 140 
were calculated using the ΔΔCt method. For calculating the ΔCt, the average of the three normalising 141 
genes (18S, RLPL0, GAPDH) was used. 142 
 143 
Extraction of HSPGs and disaccharide analysis 144 
 145 
Approximately 300 mg of frozen cartilage explants were ground in a pestle and mortar under liquid 146 
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nitrogen and the powder was placed in 1 ml of Trizol (ThermoFisher Scientific, UK). After phase 147 
separation with the addition of chloroform, the aqueous phase was added to equilibrated DEAE-148 
Sephacel beads, washed with PBS and 0.25 M NaCl before elution with 2 M NaCl. The eluate was 149 
desalted on PD10 columns and freeze dried. The samples were then treated with DNase (QIAGEN, 150 
UK) and RNase, prior to incubation with chondroitinase ABC (Sigma Aldrich, UK), neuraminidase, 151 
keratanase and pronase. Following the digestions, the samples were once more purified on DEAE beads 152 
and freeze dried. The rest of the procedure was as described before.27 Briefly, samples were sequentially 153 
digested with heparanase I, II and III (IBEX Technologies, UK), purified on C18 and graphite spin 154 
columns (ThermoFisher Scientific, UK) and labelled with BIODIPY hydrazine (ThermoFisher 155 
Scientific, UK) as previously described.28 Finally, samples underwent ethanol precipitation to remove 156 
any copurified impurities. Samples were then analysed by SAX HPLC using a Propac PA-1 strong 157 
anion-exchange column (4.6x250nm; Dionex, UK). Samples were eluted with a linear gradient of 0-1 158 
M sodium chloride and isocratic sodium hydroxide (150 mM) over 30 min at 1 ml/min on a Shimadzu 159 
HPLC system. An inline fluorimeter was used to detect eluted peaks (excitation λ = 488 nm, emission 160 
λ = 520 nm). Previously calculated correction factors were applied to quantitate the observed 161 
disaccharides.27  162 
 163 
Immunofluorescence staining analysis 164 
 165 
Upon receipt, cartilage explants were embedded in OCT (Thermofisher Scientific, UK) and frozen in 166 
isopentane for storage at -80°C until sectioning. Samples were mounted on a cryostat (CM1860UV, 167 
Leica, Milton Keynes, UK) and 5 µm sections were cut and mounted on Superfrost Plus microscope 168 
slides (ThermoFisher Scientific, UK) and stored at -80 °C. Frozen sections were air dried for 1 hour at 169 
room temperature and fixed with neutral buffered formalin for 5 minutes at room temperature prior to 170 
their incubation in ice cold acetone for 10 minutes at -20 °C, and incubated at 37 °C for 30 minutes with 171 
0.1 U chondroitinase ABC (Sigma, C3667) in 1x chondroitinase buffer (40 mM Tris-acetate, pH 8). 172 
The digested sections were blocked in 1% goat serum and 5% BSA in PBS for 1 hour at room 173 
temperature. After 15 minutes permeabilization with 0.1% Triton X-100 in PBS, sections were washed 174 
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in PBS and the primary antibodies were applied diluted in block buffer overnight at 4°C, or isotype 175 
antibodies as negative controls. The following antibodies were used: rat anti-perlecan (HSPG2) 176 
(1:1000, Millipore, UK), rabbit anti-GLCE (1:20, HPA04821, Atlas Antibodies, Sweden), rabbit anti-177 
EXTL2 (1:100, NBP2-16394, Novus, UK), mouse anti-NDST1 (3 µg/ml, ab55296, Abcam, UK), rabbit 178 
anti-GPC1 (1:250, HPA303571, Sigma, UK) and rabbit anti-HS6ST1 (1:250, ab106195, Abcam, UK). 179 
After washing in PBS at room temperature, the appropriate secondary antibodies were added; either in 180 
combination, or in unison, goat anti-rat Alexa Fluor 488 (1:1000, Thermo Fisher Scientific, UK), goat 181 
anti-rabbit Alexa Fluor 568 (1:500, Thermo Fisher Scientific, UK), or goat anti-mouse Alexa Fluor 568 182 
(1:500, Thermo Fisher Scientific, UK) in block buffer. The secondary antibodies were washed off with 183 
PBS after 3 hours at room temperature. Nuclei were stained with DAPI (1:200 in PBS, Thermo Fisher 184 
Scientific, UK) for 1 hour before a final wash in PBS and mounting in Prolong  Diamond antifade 185 
(Thermo Fisher Scientific UK).  186 
Sections were viewed under an Olympus BX51 fluorescent microscope (Olympus, UK). For each 187 
protein the optimal duration of exposure was determined as that giving a signal in positively stained 188 
sections and no detectable staining in negatively stained sections, and avoiding overexposure and signal 189 
saturation. The exposures used were: HSPG2 200-250 ms, EXTL2 125 ms, GLCE 200 ms, GPC1 125 190 
ms, NDST1 280-300 ms and HS6ST1 275-300ms. Images were obtained from at least 6 random regions 191 
of the cartilage under a 40x lens and then analysed on ImageJ as described previously.29, 30 For 192 
representative images, the intensity of the red and green signal was adjusted for illustrative purposes. 193 
For quantification, raw unaltered images  were analysed. 194 
 195 
Analysis of ERK phosphorylation in chondrocytes 196 
 197 
Primary OA chondrocytes were isolated from freshly harvested human OA cartilage by chopping the 198 
tissue finely and incubating in DMEM with 10% fetal calf serum (Gibco/ThermoFisher Scientific, UK) 199 
and 1.5 mg/ml type II collagenase (Roche, Switzerland)(18 hours,  37 °C, with shaking at 180 rpm). 200 
The suspension was passed through a cell strainer, pelleted and washed twice with medium. Isolated 201 
chondrocytes were cultured for 7 days until confluent31 and stored at -80 °C until required. For small 202 
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interfering RNA (siRNA) transfection, chondrocytes (3x105/well) were transfected with 20 nM of either 203 
Silencer Select Negative control #1 or Silencer Select HS6ST1 siRNA (s17978, Ambion/ThermoFisher 204 
Scientific, UK) using Lipofectamine 2000 (Gibco/ThermoFisher Scientific, UK) in serum free Opti-205 
MEM I (ThermoFisher Scientific).31 After 4 hours, the medium was replaced with DMEM containing 206 
10% FCS and cell cultured for a further 72 hours.  207 
To analyse ERK phosphorylation, siRNA-treated chondrocytes were cultured in serum-free DMEM 208 
for 24 hours, and treated with PBS recombinant human FGF2 (R&D Systems, USA)(20 ng/ ml, 10 209 
min). Cells were then washed twice with ice-cold PBS and lysed on ice in RIPA buffer (150 µl) 210 
containing protease inhibitors (SIGMAFAST, Sigma-Aldrich, UK) and phosphatase inhibitors (20mM 211 
NaF, 100 mM Na3VO4, 100 mM beta-glycerophosphate, 100 mM sodium pyrophosphate). Lysates were 212 
centrifuged (5000 rpm, 3 min) and 20 µg of protein analysed by immunoblotting using antibodies 213 
against phosphoERK1/2 (1:2500, E7028, Sigma-Aldrich, UK) and total ERK (1:5000, 4695S, Cell 214 
Signalling Technology, UK) in block buffer (5% milk/PBST). After 3x 5 min washes with PBST, the 215 
membranes were incubated with an AP-conjugated anti-rabbit secondary antibody (1:2000,  Promega, 216 
UK) and developed using Western Blue stabilized substrate (Promega, UK). Immunoblots were 217 
analysed by densitometry using Phoretix 1D software (TotalLab, Newcastle-upon-Tyne, UK) and the 218 
levels of phospho-ERK normalised to total ERK for each treatment, and expressed relative to the 219 
corresponding untreated sample (defined as 1). 220 
Efficacy of siRNA silencing was confirmed by isolating RNA from RIPA lysates (20 – 50 µl, diluted 221 
to 350 µl with RLT buffer containing 1% v/v β-mercaptoethanol) using RNeasy micro kits according 222 
to the manufacturer’s protocol (QIAGEN, Germany). Isolated RNA was reverse transcribed and 223 
expression of 18S, GAPDH and HS6ST1 quantified as described above.  224 
 225 
Statistical analysis 226 
 227 
All statistical tests, except correlations and linear regression models, were performed in Graphpad Prism 228 
version 7.0d. All other statistical tests were performed in R. All significant changes are annotated in the 229 
figures. 230 
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Power calculations were based on pilot data from 4 samples per group. According to the pilot 231 
experiments, we calculated the sample size required for a two-tailed t-test with an effect size of 1.5 232 
(difference between means of 0.6 and standard deviation of 0.4) and type I error rate α at 5%, to be 12 233 
samples per group. Therefore we extended the groups to the appropriate sizes. 234 
Prior to performing any parametric test, groups were tested for normality using the D’Agostino and 235 
Pearson omnibus test.32  236 
We performed two-way ANOVA and examined the forest plots (Figure 1) to evaluate whether there 237 
was significant variation in the age or sex of the donors.  238 
All tests on the PCR results were performed on the ΔΔCt values as they were normally distributed. 239 
Multiple two-tailed t-tests were performed, comparing the expression of each gene between the two 240 
groups. The derived p-values were corrected for multiplicity using the two-stage step-up method of 241 
Benjamini, Krieger and Yekutieli (BKY), with a false discovery rate cut-off at 5%.33 242 
For HS disaccharide composition, site of sulfation and extent of sulfation, two-way ANOVA was 243 
performed, with a BKY multiplicity correction. 244 
Hierarchical clustering was performed in R (https://www.r-project.org) using the package gplots 245 
ßand RColorBrewer. Canberra distance was employed as the clustering metric. 246 
For analysis of immunofluorescence images, the background-corrected integrated intensity values 247 
per cell were aggregated for the normal and OA groups (n = 3-6 per group), and the cumulative 248 
distributions of signal were analysed using the Kolmogorov-Smirnov test, since the values were not 249 
normally distributed.  250 
 251 
Results 252 
 253 
Expression of HS proteoglycan core proteins was disrupted in OA cartilage 254 
 255 
We isolated RNA from normal and osteoarthritic tibial knee cartilage (n = 12 per group), and examined 256 
expression of 13 genes encoding HS proteoglycan core proteins. Genes with a significant change in 257 
expression are shown in Figure 1.  258 
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Expression of agrin (AGRN) and perlecan (HSPG2) was significantly increased in OA samples 259 
(multiple t-tests, BKY corrected q>0.05), while expression of betaglycan (TGF β receptor III, TGFBR3) 260 
was reduced.  261 
Among the syndecan family, syndecan 2 (SDC2) was not differentially regulated between the 262 
groups, while expression of syndecan 4 (SDC4) was reduced in OA, and expression of syndecan 1 263 
(SDC1) and syndecan 3 (SDC3) was increased. SDC1 was the most strongly regulated of the HS core 264 
proteins, with mean expression increased 17-fold in OA.   265 
Glypican core proteins showed fewer changes in expression in OA cartilage, with only glypican 1 266 
(GPC1) showing significantly higher expression in OA samples. Expression of glypican 4 (GPC4), 267 
glypican 5 (GPC5) and glypican 6 (GPC6) was not significantly regulated, and glypican 2 (GPC2) and 268 
glypican 3 (GPC3) were minimally expressed in both normal and OA cartilage.  269 
 270 
Expression of HS biosynthesis and modifying enzymes was also disrupted in OA cartilage 271 
 272 
Using the same samples, we analysed expression of 25 genes encoding HS biosynthesis and modifying 273 
enzymes (Figure 1), and found that 10 of these were expressed at higher levels in OA cartilage.  274 
Expression of EXT1 and EXT2, which extend the growing HS chain, was increased in OA, as was 275 
expression of the related EXTL1 and EXTL2 genes. EXTL1 was the most strong regulated of all the 276 
genes examined, showing a 24-fold increase in expression in OA. Expression of EXLT3 was not 277 
significantly regulated. Mean expression of epimerase (GLCE), which epimerizes glucuronic acid 278 
(GluA) to iduronic acid (IdoA), was increased 2-fold in OA cartilage.  279 
Mean expression of the N-sulfotransferase NDST1 was 3-fold higher in OA cartilage.  NDST2 was 280 
expressed at similar levels in both sample groups, and NDST3 and NDST4 were not appreciably 281 
expressed in either normal or OA cartilage.  282 
Expression of the 2-O-sulfotransferase HS2ST1 was not significantly altered in OA samples. Of the 283 
7 isoforms of 3-O-sulfotransferase, only HS3ST1 showed increased expression in OA cartilage, with 284 
expression of HS3ST3A1 and HS3ST3B1 not differentially regulated and 4 of the isoforms (HS3ST2, 285 
HS3ST3, HS3ST5, HS3ST6) not detectably expressed in cartilage. Among the 3 6-O-sulfotransferases 286 
	 12	
isoforms, expression of HS6ST1 was increased in OA cartilage, while HS6ST3 expression was similar 287 
in both sample groups and HS6ST2 was expressed at low levels.  288 
Expression of both SULF1 and SULF2 was increased in OA cartilage, with HSPE and HSPE2 not 289 
differentially expressed.  290 
Cluster analysis of the samples, based on the levels of the significantly regulated genes, separated 291 
the samples into two clusters (Figure 2), with the first cluster containing all the OA samples and one of 292 
the normal samples, and the second cluster containing the remaining normal samples. This indicates 293 
that levels of expression of the 17 significantly regulated genes are largely able to discriminate normal 294 
and osteoarthritic cartilage.  295 
 296 
Selected immunohistochemical analyses validate observed changes in expression 297 
 298 
In order to establish whether the gene regulation we observed resulted in corresponding changes in 299 
protein expression, we selected six proteins (HSPG2, EXTL2, GLCE, NDST1, HS6ST1 and GPC1) to 300 
analyse by semi-quantitative immunofluorescence staining on frozen sections of normal and OA 301 
cartilage. We selected HSPG2 as a marker of pericellular matrix localisation, and the other 5 proteins 302 
according to functional antibody availability and in order to have at least one from each category of HS 303 
core proteins and biosynthetic enzymes. The intensity of staining did not vary with cartilage depth for 304 
any of the antibodies examined. 305 
As expected, HSPG2 exhibited a predominantly pericellular localization,34 with approximately 50% 306 
increased expression per cell in the 4 OA samples we examined compared to the 6 normal cartilage 307 
samples.   308 
EXTL2 had a predominantly perinuclear localization in both normal and OA cartilage (Figure 3A). 309 
In OA cartilage, expression of EXTL2 was increased 1.6-fold, with a decrease in the number of cells 310 
not expressing EXTL2 and a shift towards more cells expressing moderate amounts of the protein 311 
(Figure 3B). 312 
GLCE was similarly localized in the perinuclear region of cells (Figure 3C), with 2.4-fold higher 313 
expression in OA and a shift towards more cells expressing modest amount of the enzyme (Figure 3D). 314 
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HS6ST1 intensity levels were approximately 3 times higher in OA (Figure 4B). The protein appeared 315 
to be expressed at low levels around the nucleus in normal cartilage and to show some pericellular 316 
staining in the OA samples (Figure 4A). 317 
NDST1 was localized in the perinuclear region in normal cells, with more expression towards the 318 
periphery of the cell and overlapping with HSPG2 in the OA samples (Figure 4C). Intensity levels were 319 
approximately 3.6-fold higher in the OA samples (Figure 4D).  320 
Staining for GPC1 was predominantly intracellular (Figure 5A), with 5.5-fold higher intensity in 321 
OA samples (Figure 5B). 322 
 323 
Increased 6-O-sulfation of HS in OA cartilage 324 
 325 
We analyzed the amount and disaccharide composition of HS isolated from normal and OA cartilage 326 
(n = 8 per group, Figure 6A).  327 
There was no significant difference in the total amount of HS in the normal and OA cartilage 328 
samples (5.7 ± 2.3 µg/100 mg in the normal samples, 3.0 ± µg/100 mg of tissue in OA, P >0.05 by t-329 
test, Figure 6B), or in the ratio of sulfated to total HS disaccharides (36.5 % in normal cartilage, 53% 330 
in OA cartilage, Mann Whitney test, P >0.05, Figure 6C).  331 
Normal and OA cartilage did not differ significantly in the abundance of any single HS disaccharide 332 
(Figure 6D), or in the percentages of non-, mono-, di or triple- sulfated disaccharides (not shown). 333 
However, the percentage of 6-O-sulfated disaccharides was increased in OA cartilage (19.8% vs 12.1%, 334 
Mann Whitney test, P = 0.0379, Figure 6E). 335 
 336 
6-O-sulfation of HS correlated with expression of GLCE, HS6ST1, EXTL2 and HS3ST3A1 337 
 338 
We examined whether expression of any of HS biosynthesis genes correlated with the HS disaccharide 339 
compositions quantified.  340 
The percentage of 6-O-sulfated disaccharides correlated with expression of HS6ST1 (r = 0.74, p = 341 
0.0016, Figure 6F), GLCE (r = 0.775, p = 0.0007, Figure 6G), EXTL2 (r = 0.57, p = 0.026), and 342 
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HS3ST3A1 (r = 0.575, p = 0.025).  The relationship between 6-O-sulfation and HS6ST1 expression was 343 
linear, with a 4% increase in abundance of 6-O-sulfated disaccharides for every doubling in the amount 344 
of HS6ST1 (adjusted R2 = 0.525, p = 0.0014). This relationship was independent of age, OA and gender. 345 
The relationship between 6-O-sulfation and GLCE expression was linear, with a doubling in expression 346 
of GLCE increasing the percentage of 6-O-sulfation by about 4%. This relationship was dependent on 347 
age and gender, such that for every year increase in age there was a 0.17% increase in % 6-O-sulfation, 348 
and that females had about 4% more 6-O-sulfation for the same amount of GLCE (adjusted R2 = 0.42, 349 
p = 0.028).  350 
The percentage of 2-O-sulfated disaccharides correlated with expression of HS3ST3A1 (r = 0.796, p 351 
= 0.0004) and HS6ST1 (r = 0.57, p = 0.026). The relationship between 2-O-sulfation and HS3ST3A1 352 
expression was linear, with a doubling in the levels of HS3ST3A1 increasing the percentage of 2-O-353 
sulfated disaccharides by 4%. This association was OA- and gender-dependent, such that females with 354 
OA had a 0.62% increase in 2-O-sulfation for the same level of HS3ST3A1expression (adj R2 = 0.67, p 355 
= 0.0036). 356 
We also examined correlations between expression of HS biosynthesis genes and the relative 357 
abundance of individual disaccharide residues. This showed that HS3ST3A1 expression correlated with 358 
the percentage of UA(2S)-GlcNAc (r = 0.772, P < 0.05), UA(2S)-GlcNS (r = 0.538, P < 0.05) and UA-359 
GlcNS(6S) (r = 0.521, P < 0.05), while HS6ST1 expression correlated with the percentage of UA(2S)-360 
GlcNAc (r = 0.53, P < 0.05), UA-GlcNAc(6S) (r = 0.58, P < 0.05) and UA-GlcNAc (r = -0.686, P = 361 
0.005).  362 
Finally, we found that HS3ST2 expression was linearly associated with age, independent of OA and 363 
gender, with expression of HS3ST2 increasing by 6-21% every year (adj R2 =0.341, p = 0.035). 364 
 365 
siRNA silencing of HS6ST1 inhibits FGF2 signalling  366 
 367 
To  investigate whether changes in HS6ST1 expression and 6-O-sulfation have the capacity to alter 368 
signalling in OA chondrocytes, we isolated chondrocytes from knee cartilage of 5 donors with late-369 
stage OA, and examined FGF2-dependent ERK phosphorylation after siRNA knockdown of HS6ST1. 370 
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siRNA treatment suppressed HS6ST1 mRNA levels by >90% in all 5 donors (Figure 6H). Addition of 371 
20 ng/ml FGF-2 stimulated rapid phosphorylation of ERK, and this was significantly reduced (by 40%) 372 
in HS6ST1-silenced cells (Figure 6I).   373 
 374 
Discussion 375 
 376 
HS proteoglycans control the retention, localization and biological activity of over 400 bioactive 377 
molecules, including growth factors (e. g. FGF2, TGFβ), morphogens (e. g. BMP-4, BMP-7), 378 
proteinases (e. g. MMP-13, ADAMTS-4, ADAMTS-5) and proteinase inhibitors (e. g. TIMP-3).4, 35-37 379 
Many HS ligands have significant impacts on cartilage homeostasis, making HS a critical regulator of 380 
joint health. Despite this important role, nothing was previously known about how the structure and 381 
sulfation pattern of HS may change during the development of osteoarthritis. Here, we report that 382 
expression of HS biosynthesis and modifying enzymes and the resulting HS disaccharide composition 383 
differs significantly in normal and osteoarthritic human knee cartilage.  384 
Expression of the HS polymerases EXT1 and EXT2, as well as EXTL1 and EXTL2, was significantly 385 
increased in OA cartilage. The roles of these enzymes in homeostasis of adult cartilage has not been 386 
explored, but EXT1 and EXT2 are known to be important in musculoskeletal development. EXT1 387 
regulates Ihh signalling during endochondral ossification,38 and mutations in both EXT1 and EXT2 are 388 
associated with development of hereditary multiple exostoses, an inherited pediatric disorder 389 
characterised by osteochondroma formation.39 Aberrant activation of chondrocyte hypertrophy has been 390 
implicated in development of OA,40 and may underlie the elevated expression of EXT1 and EXT2 we 391 
observed. The role of the related EXTL genes in HS synthesis are less well understood, but they are 392 
thought to regulate early stages of HS chain elongation.41 Mutations in EXTL3 have been shown to 393 
impair musculoskeletal development,42 and while EXTL3 expression was not regulated in OA, 394 
expression of both EXTL1 and EXTL2 was strongly upregulated.  395 
Once polymerised, the HS chain can be modified by epimerisation of GlcA to IdoA by a glucuronyl 396 
epimerase (GLCE), or by addition of sulfate groups to specific positions in the disaccharide units, by 397 
multiple sulfotransferases. We measured expression of the 11 human HS sulfotransferases, and found 398 
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that expression of NDST1, HS3ST1 and HS6ST1 was elevated in OA cartilage. Most notably, we found 399 
a significant increase in the level of 6-O-sulfated disaccharides in OA cartilage, which correlated 400 
strongly with expression of both HS6ST1 and GLCE. Epimerisation of GlcA to IdoA by GLCE is 401 
thought to favour subsequent 6-O-sulfation,43 suggesting that these two enzymes drive the increase in 402 
6-O-sulfation in OA cartilage. Previous studies have shown that levels of 6-O-sulfation are spatially 403 
and temporally regulated during development,18, 19, 21 and in diseases such as fibrosis,44, 45 Alzheimer’s 404 
disease,22 and cancer.46, 47 In the case of fibrosis, a doubling in 6-O-sulfation is thought to exacerbate 405 
disease by amplifying TGFβ44 and FGF-245 signaling. We hypothesized that increased 6-O-sulfation in 406 
OA cartilage may similarly amplify downstream signalling pathways and alter tissue homeostasis. 407 
Consistent with this, using primary OA chondrocytes isolated from 5 different donors, we found that 408 
siRNA silencing of HS6ST1 suppressed ERK phosphorylation in response to FGF2. This is in line with 409 
previous studies showing that 6-O-sulfation of HS promotes FGF2 signalling,48-51 and confirms that 410 
changes in 6-O-sulfation can alter biologically relevant signalling pathways in cartilage. 6-O-sulfation 411 
is known to alter HS affinity for a range of ligands,52 with varying effects on their downstream activity. 412 
For example, 6-O-sulfation promotes TGFβ53, 54 signalling, and inhibits Wnt55, 56 and BMP57, 58 413 
signalling. An unbiased approach such as phosphoproteomics will be required to identify pathways 414 
regulated by 6-O-sulfation in normal and OA cartilage. 415 
The importance of 6-O-sulfation is underscored by the fact that it is the only HS modification that 416 
is regulated at both the ‘on’ and the ‘off’ level, being added during HS biosynthesis in the Golgi 417 
apparatus by HS6ST1, HS6ST2 and/or HS6ST343 and removed in the extracellular environment by the 418 
6-O-endosulfatases SULF1 and/or SULF2.59 This permits “remodelling” of HS sulfation that is 419 
apparently critical to regulation of its functions. Indeed, we observed increased expression of SULF1 420 
and SULF2 in OA cartilage, in line with previous reports examining both human and murine OA 421 
cartilage.7, 9, 11, 58, 60, 61 Despite this, net levels of 6-O-sulfation were increased in our OA cartilage 422 
samples. As noted in recent studies from HS in muscle,27 this highlights the importance of analysing 423 
HS structure directly, and may indicate post-translational regulation of HS6ST and/or SULF activity, 424 
or differences in the catalytic efficiency, location or stability of the enzymes.  Sulf1-/- and Sulf2-/- mice 425 
developed accelerated OA and injection of recombinant SULF1 into the joint reduced cartilage 426 
	 17	
damage,62 indicating the enzymes play a chondroprotective role. This suggests that elevated 6-O-427 
sulfation may contribute to or perpetuate cartilage damage, potentially through driving anabolic 428 
pathways or impairing catabolic repair mechanisms.  429 
We did not find any increase in N-sulfation in OA cartilage, despite increased expression of NDST1 430 
at the mRNA and protein level. We did not quantify the abundance of 3-O-sulfated disaccharides due 431 
to their relative scarcity, but expression of HS3ST1 was elevated in OA samples. Further investigation 432 
may be warranted as knowledge of the functional impact of 3-O-sulfation and the extent of the 3-O-433 
proteome expands.63, 64   434 
With regards the HS core proteins, we observed the previously reported increase in expression of 435 
HSPG26-9, glypican 1,11 syndecan 19-11 and syndecan 365 in OA cartilage, but not the previously 436 
observed increase in syndecan 49, 11-13  or decrease in agrin.66 This may suggest species- or joint-specific 437 
variation in expression of these genes. Additionally, we observed that expression of many HS-438 
associated genes was significantly altered by isolation and culture of chondrocytes (data not shown), 439 
suggesting that HS biosynthesis is dynamically regulated by the chondrocyte microenvironment and 440 
that expression may change during the course of OA development. 441 
We observed a significant reduction in expression of TGFBR3 in OA cartilage. This HS core protein, 442 
also known as beta-glycan, does not have the ability to signal directly, but promotes TGFβ signalling 443 
by recruiting the growth factor and presenting it to the type II TGFβ receptor. In chondrocytes, TGFBR3 444 
was recently shown to promote activation of latent TGFβ in a CTGF- and HS-dependent manner.67 445 
Reduction in expression of TGFBR3 in OA is thus likely to impair the chondroprotective effects of 446 
TGFβ signalling.  447 
Previous rodent microarray studies indicate that expression of some HS core proteins, biosynthesis 448 
and modifying enzymes is regulated early in the course of OA development.7, 8, 11, 68-72 For example, 449 
expression of Ext1,11, 68 Sdc1, 11, 68, 69 Gpc1, 11, 69 and Hspg211, 68 is significantly increased within 2-4 450 
weeks of surgical OA induction (Supplementary Table 1), in line with our findings here. Data on early 451 
changes in expression of sulfotransferases are variable, and early changes in Hs6st1 were not reported. 452 
This may suggest that expression of this gene is stimulated once cartilage damage starts to escalate, but 453 
may also reflect differences between rodent post-traumatic OA and more variable human disease.  454 
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Age is a primary risk factor for the development of OA, and it is important to understand the cellular 455 
mechanisms that increase risk with age if we are to develop effective therapies to treat the disease. 456 
Previous studies have shown that HS sulfation patterns change with age in various tissues, including 457 
the aorta,73 myocardium,74 muscle stem cell niche27 and brain,75, 76 with concomitant changes in growth 458 
factor signalling. While our study was not powered to detect changes in HS disaccharide composition 459 
with age, we found that expression of HS3ST2 in cartilage increased with age, in contrast to what has 460 
previously been reported in skin.77 However, our observation is based on a low number of individuals 461 
(n = 11) as we had some missing values for HS3ST2 expression. Further analysis of age-dependent 462 
changes in HS structure may identify changes that impair cartilage repair with age and so increase the 463 
risk of OA after injury.  464 
Our analysis identified 6-O-sulfation as the primary HS motif that is altered in end-stage OA 465 
cartilage, validating it as a new target for potential therapeutic interventions. To understand the impact 466 
this change has on cartilage repair and OA progression, it will be necessary to carry out unbiased 467 
analyses of the 6-O-sulfate-binding proteome in normal and OA cartilage. Comparative mass 468 
spectrometry approaches have proved useful in examining the 3-O-sulfate-binding proteome in cultured 469 
cells,64 and similar methods could be developed for cartilage analysis. Analysis of other joint tissues (e. 470 
g. bone, synovium, meniscus) and earlier stages of OA progression can also be expected to shed further 471 
light on the role of HS in adult joint homeostasis.    472 
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Table 1: Primer/probe sets used on custom-designed Taqman low density arrays. 698 
     699 
Gene name Primer/probe set 
Chain elongation 
EXT1 Hs00609162_m1 
EXT2 Hs00181158_m1 
EXTL1 Hs00184929_m1 
EXTL2 Hs01018237_m1 
EXTL3 Hs00918601_m1 
N-deacetylase/ N-sulfotransferases 
NDST1 Hs00925442_m1 
NDST2 Hs00234335_m1 
NDST3 Hs01128584_m1 
NDST4 Hs00224024_m1 
Glucuronyl C5-epimerase 
GLCE Hs00392011_m1 
2-O-sulfotransferase 
HS2ST1 Hs00202138_m1 
3-O-sulfotransferases 
HS3ST1 Hs00245421_s1 
HS3ST2 Hs00428644_m1 
HS3ST3A1 Hs00925624_s1 
HS3ST3B1 Hs00797512_s1 
HS3ST4 Hs00901124_s1 
HS3ST5 Hs00999394_m1 
HS3ST6 Hs03007244_m1 
6-O-sulfotransferases 
HS6ST1 Hs00757137_m1 
HS6ST2 Hs02925656_m1 
HS6ST3 Hs00542178_m1 
Editing enzymes 
HSPE Hs00935036_m1 
HSPE2 Hs00222435_m1 
SULF1 Hs00290918_m1 
SULF2 Hs01016476_m1 
Core proteins 
AGRN Hs00394748_m1 
GPC1 Hs00892476_m1 
GPC2 Hs00415099_m1 
GPC3 Hs01018936_m1 
GPC4 Hs00155059_m1 
GPC5 Hs00270114_m1 
GPC6 Hs00170677_m1 
HSPG2 Hs00194179_m1 
SDC1 Hs00896423_m1 
SDC2 Hs00299807_m1 
SDC3 Hs01568665_m1 
SDC4 Hs00161617_m1 
TGFBR3 Hs01114253_m1 
Normalising genes 
18S Hs99999901_s1 
RPLP0 Hs99999902_m1 
GAPDH Hs99999905_m1 
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 700 
Figure 1.  Changes in HS-related gene expression in human OA cartilage. Expression of HS-associated 701 
genes in normal and OA cartilage (n = 12 per group) was analysed using Taqman low-density arrays. 702 
Fold changes in expression were determined by the ΔΔCt method against the average of the normal 703 
	 30	
samples. A: Fold changes in expression of HS core protein genes. B: Fold changes in expression of HS 704 
chain elongation and sulfatase genes. C: Fold changes in expression of sulfotransferase genes. Error 705 
bars represent 95% of confidence intervals of the mean. ** q <0.01, *** q < 0.001, **** q < 0.0001 by 706 
BKY corrected multiple t-test.   707 
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 708 
Figure 2.  Expression of HS-associated genes is altered in OA cartilage. A: Forest plot showing there 709 
was no significant difference between the ages and genders of normal (n = 12) and OA (n = 12) cartilage 710 
donors used for gene expression analysis. M, male; F, female. Bars show 95% confidence intervals of 711 
the mean, dotted line shows Y=0. B: Expression of HS-associated genes in normal and OA cartilage 712 
was analysed using Taqman low-density arrays. Fold change in expression were determined by the 713 
ΔΔCt method against the average of the normal samples. The heatmap shows only those HS-associated 714 
genes whose expression was significantly different in the two groups (n = 12 for each group; BKY 715 
corrected multiple t-test; q-value < 0.05), with increased expression in OA shown in red, reduced 716 
expression shown in blue, and no change indicated in green. Cluster analysis based on the expression 717 
levels of significantly regulated genes separated the samples into two clusters, with the first cluster 718 
containing all of the OA samples and one of the normal samples, and the second cluster containing the 719 
remaining normal samples.  720 
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Figure 3.  Expression of HSPG2, EXTL2 and GLCE is increased in human OA cartilage. A: 722 
Representative images showing expression of HSPG2 and EXLT2 in human normal and OA cartilage.  723 
B: Expression of HSPG2 and EXLT2 was semi-quantitatively evaluated in 3 normal donors (N1, N2 724 
and N3) and 3 OA donors (OA1, OA2 and OA3), with each dot representing integrated fluorescence 725 
intensity per single cell, calculated from at least 6 random fields of view on 3 sections per donor. For 726 
each donor, the median fluorescence intensity with 95% confidence intervals of the mean are shown. 727 
C: Representative images showing expression of HSPG2 and GLCE in human normal and OA cartilage. 728 
D: Expression of HSPG2 and GLCE was semi-quantitatively evaluated in 3 normal donors (N4, N5 729 
and N6) and 3 OA donors (OA1, OA2 and OA4) as described in B. ** P < 0.01, *** P < 0.001, **** 730 
P < 0.0001 by Kolmogorov-Smirnov test. Scale bar = 260 µm.   731 
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Figure 4.  Expression of HSPG2, HS6ST1 and NDST1 is increased in human OA cartilage. A: 733 
Representative images showing expression of HSPG2 and HS6ST1 in human normal and OA cartilage.  734 
B: Expression of HSPG2 and HS6ST1 was semi-quantitatively evaluated in 3 normal donors (N4, N5 735 
and N6) and 3 OA donors (OA1, OA2 and OA4), with each dot representing integrated fluorescence 736 
intensity per single cell, calculated from at least 6 random fields of view on 3 sections per donor. For 737 
each donor, the median fluorescence intensity with 95% confidence intervals of the mean are shown. 738 
C: Representative images showing expression of HSPG2 and NDST1 in human normal and OA 739 
cartilage. D: Expression of HSPG2 and NDST1 was semi-quantitatively evaluated in 3 normal donors 740 
(N1, N2 and N3) and 3 OA donors (OA1, OA2 and OA3) as described in B. *P < 0.05, **** P < 0.0001 741 
by Kolmogorov-Smirnov test. Scale bar = 260 µm.  742 
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 743 
Figure 5.  Expression of HSPG2 and glypican 1 (GPC1) is increased in human OA cartilage. A: 744 
Representative images showing expression of HSPG2 and GPC1 in human normal and OA cartilage. 745 
B: Expression of HSPG2 and GPC1 was semi-quantitatively evaluated in 3 normal donors (N1, N2 and 746 
N3) and 3 OA donors (OA1, OA2 and OA3), with each dot representing integrated fluorescence 747 
intensity per single cell, calculated from at least 6 random fields of view on 3 sections per donor. For 748 
each donor, the median fluorescence intensity with 95% confidence intervals of the mean are shown.  749 
** P < 0.01 by Kolmogorov-Smirnov test. Scale bar = 260 µm.   750 
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751 
Figure 6.  6-O-sulfation is increased in OA cartilage. HS was isolated from normal (n = 8) and OA (n 752 
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= 8) cartilage and its composition analyzed by disaccharide analysis. A: Forest plot showing there was 753 
no significant difference between the ages and genders of normal (n = 8) and OA (n = 8) cartilage 754 
donors used for HS analysis. M, male; F, female. Bars show 95% confidence intervals of the mean , 755 
dotted line shows Y=0. B: The total amount of HS in OA cartilage was not statistically different from 756 
that in normal cartilage. C: The ratio of sulfated to total HS was not statistically different between the 757 
two groups of samples. D: Abundance of individual disaccharide species was not significantly different 758 
in normal and OA cartilage. GlcNAc, N-acetyl glucosamine; GlcNS, N-sulfoglucosamine; UA, uronic 759 
acid; 2S,  2-O-sulfate; 6S, 6-O-sulfate. E: 6-O-sulfated HS disaccharides were more abundant in OA 760 
cartilage, while levels of N- and 2-O-sulfation were not significantly altered. F: The level of 6-O-761 
sulfation in donor cartilage correlated with expression of HS6ST1 (n = 15, normal cartilage shown in 762 
black, OA cartilage in grey, males as squares, female samples as circles). G: The level of 6-O-sulfation 763 
in donor cartilage also correlated with expression of GLCE (n = 15, normal cartilage shown in black, 764 
OA cartilage in grey, males as squares, female samples as circles). H: Expression of HS6ST1 in primary 765 
OA chondrocytes was silenced using siRNA (n = 5  donors). NT, transfected with non-targeting siRNA. 766 
I: Silencing of HS6ST1 in primary OA chondrocytes reduced phosphorylation of ERK in response to 767 
FGF2 (20 ng/ml, 10 min)(n = 5 donors).  *P < 0.05, ** P <0.01, *** P < 0.001, multiple t-tests BKY 768 
corrected.  769 
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Supplementary Table 1: Changes in expression of HS biosynthesis and modifying genes, adapted 770 
from published murine and human transcriptome datasets. Gardiner11 and Loeser68 examined 771 
changes in gene expression after surgical induction of OA in mice by destabilisation of the medial 772 
meniscus (DMM), while Appleton69 used the more severe ACLT (anterior cruciate ligament 773 
transection) model in rats. For the human studies, late-stage damaged OA cartilage was compared to 774 
normal cartilage (Karlsson7 and Sato8) or to macroscopically intact cartilage from the same OA joint 775 
(Geyer,70 Dunn,71 and Snelling72).  776 
 777 
 Rodent – early OA Human – late stage OA 
Gardiner Appleton Loeser Karlsson Geyer Sato Dunn Snelling 
2 weeks 
post DMM 
4 weeks 
post 
ACLT 
4 weeks 
post 
DMM 
OA vs 
normal 
OA lesion 
vs intact 
OA vs 
normal 
OA 
lesion vs 
intact 
OA lesion 
vs intact 
Up in OA Ext1  Ext1 EXTL2 EXTL2    
 Sdc1 Sdc1 Sdc1      
 Sdc2 Sdc2 Sdc4      
 Gpc1 Gpc1    GPC5 GPC4  
  Gpc2 Gpc6      
 Hspg2  Hspg2 HPGS2  HPGS2   
 Sulf2  Sulf1 SULF1     
 Hs2st1      HS3ST2 HS3ST3A1 
       HSPE2  
Down in OA Extl1      EXTL1  
 Sdc4      SDC3 SDC3 
       GPC5 GPC4 
     GPC6  GPC6  
 Tgfbr3    TGFBR3    
 Hs3st3a1 Hs3st1  HS3ST3A1     
 Hs3st3b1   HS3ST3B1     
        SULF1 
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